Recent Updates
Recently added Catalysts

RXIM002

Phase 1

Immune Thrombocytopenia (ITP) | Monoclonal antibody | Hematology |cbdMD, Inc.|Last Updated: Aug 27, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment27

FDA Designations

No designations recorded

Clinical trial landscape

RXIM002 · 1 trial · 1 indication

Phase 1 1
NCT07765966Phase 1 Dose Escalation Study of RXIM002 in Autoimmune CytopeniasImmune Thrombocytopenia (ITP)
NOT YET_RECRUITING27 Analytics
PHASE1NOT YET_RECRUITING
Phase 1 Dose Escalation Study of RXIM002 in Autoimmune Cytopenias
Immune Thrombocytopenia (ITP)
NCT0776596627
Unlock trial analytics

Study Endpoints

Primary Endpoints

Incidence of treatment-emergent adverse events
Up to 104 weeks
Dose-limiting toxicities (DLTs)
Through Day 28 post-first dose
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
RXIM002EXPERIMENTALOpen-label, single arm with 3 dose-level cohorts of RXIM002

Interventions

NameTypeDescription
RXIM002BIOLOGICALTargeted lipid nanoparticle (tLNP)-delivered circular ribonucleic acid (circRNA) encoding an anti-human CD19 chimeric antigen receptor (CAR)
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 75 Years
SexALL
Healthy VolunteersNo

Inclusion Criteria: * 18-75 years of age * Diagnosed with primary ITP * Relapsed or refractory ITP Exclusion Criteria: * Allergy or hypersensitivity to messenger ribonucleic acid (mRNA) vaccines or other RNA-LNP products * Any active infection * Heart failure, reduced kidney function, or liver ab...

Unlock Eligibility Criteria